# NuvoAir

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nuvoair

- Industry: Medical Devices & Equipment
- Headquarters: Stockholm, Sweden
- Website: www.nuvoair.com
- Total disclosed funding: $23M
- Latest round: Series A (Jan 19, 2022)
- Investors on record: 7

## About

NuvoAir AB is a Swedish company specializing in telehealth solutions that enhance the management of chronic respiratory and cardiovascular conditions through innovative monitoring devices and virtual healthcare services.Founded in 2015 and headquartered in Stockholm, Sweden, NuvoAir AB focuses on delivering effective telehealth solutions for patients with chronic conditions. The company was founded by Lorenzo Consoli, who has a background in healthcare innovation. In January 2022, NuvoAir AB raised USD 11 mn in Series A funding led by Hikma Ventures. The funding will be utilized to expand their patient-centric care and clinical trials platform, underscoring the company’s commitment to improving healthcare delivery.NuvoAir provides a comprehensive telehealth platform focusing on the management of chronic conditions related to heart and lung health. Their offerings include FDA-approved health monitoring devices such as the Air Next spirometer, pulse oximeter, activity tracker, and blood pressure cuff. The platform serves patients with conditions like asthma, COPD, and heart failure, facilitating real-time health monitoring and virtual appointments with specialized healthcare professionals. By integrating personalized health coaching and evidence-based health programs, NuvoAir aims to empower patients in managing their health effectively.In 2022, NuvoAir reported a revenue of USD 4,143,549.50 with an EBITDA of USD -4,892,974.70. Their revenue model is primarily driven by insurance reimbursements, with services covered by major insurance providers, including Medicare and Medicaid. The company utilizes a subscription-based model that provides ongoing support and personalized care plans for patients.NuvoAir plans to leverage the USD 11 mn raised in Series A funding to enhance their patient-centric care and clinical trials platform. The company is expected to target new geographic regions and markets for expansion, though specific locations and timelines have not been disclosed. The funding will support the development of upcoming products aimed at improving chronic condition management.

## Funding rounds

- Series A, Jan 19, 2022, $11M — Hikma Ventures
- Series A, Jun 22, 2021, $12M — Spiltan, Industrifonden, dRx Capital, AlbionVC, Amino Collective, KAYA

## Investors

- Spiltan — Series A
- Industrifonden (https://capitalatlas.ai/funds/industrifonden) — Series A
- dRx Capital (https://capitalatlas.ai/funds/drx-capital) — Series A
- AlbionVC — Series A
- Amino Collective (https://capitalatlas.ai/funds/amino-collective) — Series A
- KAYA (https://capitalatlas.ai/funds/kaya) — Series A
- Hikma Ventures (https://capitalatlas.ai/funds/hikma-ventures) — Series A